Long-Term Treatment of Tardive Dyskinesia with Haloperidol and Tetrabenazine
Abstract
Thirteen patients with tardive dyskinesia were treated with either haloperidol or tetrabenazine for 18 weeks. Haloperidol produced a statistically significant reduction in the frequency of oral dyskinesia, though the effect was most striking during the first two weeks; reversible extrapyramidal symptoms appeared to be negatively correlated with oral dyskinesia. Tetrabenazine also produced a significant reduction in the frequency of oral dyskinesia, with almost complete suppression in two patients throughout the study; the correlation between oral dyskinesia and reversible extrapyramidal symptoms was less clear than with haloperidol. No exacerbation of the dyskinesia was observed after administration of the study drugs was discontinued.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).